7 completed, 4 active not recruiting, 1 not yet recruiting, 1 recruiting. 15 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 15 | Completed 7, Active not recruiting 4, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS) Dimethyl Fumarate Enteric-coated Capsules - Relapsing Multiple Sclerosis | Phase 4 | Not yet recruiting | Qilu Pharmaceutical (Hainan) Co., Ltd. | 50 | 2025-09-01 | 2025-08-24 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Ocrelizumab - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 4 | Active not recruiting | Hoffmann-La Roche | 60 | 2025-07-04 | 2026-09-30 |
| Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod Ozanimod - Relapsing Multiple Sclerosis | Phase 4 | Recruiting | University of Colorado, Denver | 100 | 2024-07-29 | 2025-09-18 |
| A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis BMS-986374 - Relapsing Multiple Sclerosis | Phase 4 | Active not recruiting | Bristol-Myers Squibb | 84 | 2024-05-15 | 2025-04-16 |
| Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China Ofatumumab - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 99 | 2022-07-22 | 2026-01-13 |
| Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab Ofatumumab - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 34 | 2021-05-27 | 2025-05-16 |
| Effects of Ocrevus in Relapsing Multiple Sclerosis Ocrelizumab, Platform - Relapsing Multiple Sclerosis | Phase 4 | Active not recruiting | Georgia State University | 60 | 2021-02-05 | 2026-06-17 |
| A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Quadrivalent influenza vaccine, Ofatumumab, iDMT - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 63 | 2021-01-14 | 2024-10-09 |
| Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset Ocrelizumab - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Active not recruiting | University of California, San Francisco | 30 | 2020-08-30 | 2026-01-26 |
| To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis TERIFLUNOMIDE HMR1726 - Relapsing Multiple Sclerosis | Phase 4 | Completed | Sanofi | 121 | 2019-03-27 | 2023-04-19 |
| A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Fingolimod - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 382 | 2017-09-19 | 2021-10-07 |
| Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ Rebif - Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Completed | Merck KGaA, Darmstadt, Germany | 106 | 2014-12-31 | 2018-03-30 |
| Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy Interferon Beta, BIIB017 (Peginterferon beta-1a) - Relapsing Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2014-10-01 | 2014-11-17 | |
| Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies natalizumab - Relapsing Multiple Sclerosis | Phase 4 | Terminated | Biogen | 47 | 2014-09-30 | 2017-06-05 |
| The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial Blood sampling - Relapsing Multiple Sclerosis | Phase 4 | Completed | EMD Serono | 324 | 2010-02-01 | 2014-03-10 |
Multiple Sclerosis (3) · COVID-19 (1) · Multiple Sclerosis, Chronic Progressive (1)
Autoimmune Diseases (4) · Autoimmune Diseases of the Nervous System (4) · Demyelinating Autoimmune Diseases, CNS (4) · Demyelinating Diseases (4) · Immune System Diseases (4) · Nervous System Diseases (4) · Chronic Disease (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Disease Attributes (1) · Infections (1) · Lung Diseases (1) · Multiple Sclerosis (1) · Nidovirales Infections (1) · Pathologic Processes (1)
ocrelizumab (3) · ofatumumab (3) · Interferon beta-1a (2) · ozanimod (2) · Blood Specimen Collection (1) · Fingolimod Hydrochloride (1) · Influenza Vaccines (1) · Interferon beta-1b (1) · Interferon-beta (1) · Natalizumab (1) · peginterferon beta-1a (1) · teriflunomide (1)
Novartis Pharmaceuticals (4) · Biogen (2) · Bristol-Myers Squibb (1) · EMD Serono (1) · Georgia State University (1) · Hoffmann-La Roche (1) · Merck KGaA, Darmstadt, Germany (1) · Qilu Pharmaceutical (Hainan) Co., Ltd. (1) · Sanofi (1) · University of California, San Francisco (1) · University of Colorado, Denver (1)
United States (7) · China (3) · Germany (2) · India (1)
Bruce Cree, MD, PhD, MAS (1) · Elisabetta Verdun di Cantogno, MD (1) · Enrique Alvarez, MD/PhD (1) · Feng Yang, PhD (1)
2014 (1)